<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="31415"><DrugName>GT-2394</DrugName><DrugSynonyms><Name><Value>GT-2394</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>H3 antagonists (obesity), Merck &amp; Co</Value></Name><Name><Value>186194-49-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16483">Gliatech Inc</CompanyOriginator><CompaniesSecondary><Company id="16483">Gliatech Inc</Company><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="31415" type="Drug"><TargetEntity id="302129" type="siDrug">GT-2394</TargetEntity></SourceEntity><SourceEntity id="16483" type="Company"><TargetEntity id="4295906600" type="organizationId">Gliatech Inc</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="Action"><TargetEntity id="198" type="Mechanism">Histamine H3 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00917" type="ciTarget"><TargetEntity id="952367692112553" type="siTarget">Histamine H3 receptor</TargetEntity><TargetEntity id="114271494" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="238">Obesity</Indication></IndicationsSecondary><ActionsPrimary><Action id="203">Histamine H3 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1840">Appetite suppressant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-30T09:59:25.000Z</LastModificationDate><ChangeDateLast>2006-05-05T14:24:04.000Z</ChangeDateLast><AddedDate>2000-11-06T14:45:54.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16483" linkType="Company"&gt;Gliatech&lt;/ulink&gt; was investigating GT-2394 (structure shown), a histamine H3 antagonist, for the potential treatment of obesity [&lt;ulink linkID="388484" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="387683" linkType="Reference"&gt;387683&lt;/ulink&gt;].  However, by November 2002, GT-2394 and its associated technology had been sold to Merck  [&lt;ulink linkID="469832" linkType="reference"&gt;469832&lt;/ulink&gt;]; since the acquisition, no further development has been reported by Merck.    &lt;/para&gt;&lt;para&gt;GT-2394 is one of a number of H3 antagonists which were under investigation at Gliatech for a variety of indications, including &lt;ulink linkID="7524" linkType="Drug"&gt;GT-2016&lt;/ulink&gt; (qv) and &lt;ulink linkID="7928" linkType="Drug"&gt;GT-2331&lt;/ulink&gt; (qv) [&lt;ulink linkID="388484" linkType="reference"&gt;388484&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2003, preclinical data on GT-2394 were presented by Gliatech at the 225th ACS meeting in New Orleans, LA. The compound was shown to have IC50 values of greater than 100,000, 11,200 and 2.9 nM against the H1, H2 and H3 receptor , respectively, indicating good selectivity for H3. Ex vivo, GT-2394 had an ED50 value of 3.0  mg/kg, and time-dependent elimination (80% at 2 h; 20% at 18 h) was observed. In an acute food-intake test in Sprague-Dawley rats (10 mg/kg ip), food intake was reduced from 30 g for vehicle to 20 g after 24 h. The compound was no longer effective after 24 h, however, there was no compensation for the earlier reduced food intake, and there was no impact on water intake. In a subchronic evaluation (10 mg/kg), the average decrease in food intake was 12.0% and the total body weight decreased by 4.6% [&lt;ulink linkID="483119" linkType="reference"&gt;483119&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2002, preclinical data on GT-2394 were presented at the 32nd Neuroscience meeting in Orlando, FL. A series of high-affinity histamine H3 receptor antagonists, including GT-2394, were evaluated by Gliatech for their effects on food intake at doses which produce maximal CNS receptor occupancy. Inverse agonists, compounds which displayed higher affinity binding to G-protein uncoupled receptors, produced a reduction in food intake. However, those which did not display preferential binding to either coupled or uncoupled receptors, did not effect a reduction in food intake. GT-2394, an inverse agonist, produced a consistent lowering of food intake associated with a reduction in bodyweight gain following daily administration for 2 weeks. GT-2394 produced no adverse clinical signs during this period [&lt;ulink linkID="469148" linkType="reference"&gt;469148&lt;/ulink&gt;], [&lt;ulink linkID="469148" linkType="reference"&gt;469148&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2000, optimization studies had led to the identification of GT-2394, which has an ED50 value of 3 nM for the H3 receptor, with low affinity at H1 and H2. The compound exhibits an ED50 binding value of 3 mg/kg ex vivo following oral administration of 10 mg/kg, it has a rapid receptor occupancy (within 30 min), is eliminated within 8 h, and has a half-life of 3 to 4 h. At this dose it also significantly decreased food intake after 1 h, which was maintained up to 4 h. In addition, despite its 8 h clearance, food intake was still depressed after 24 h. Sub-chronic dosing led to a 12% decrease in body weight, with no locomotor stimulatory activity [&lt;ulink linkID="388484" linkType="reference"&gt;388484&lt;/ulink&gt;], [&lt;ulink linkID="387683" linkType="reference"&gt;387683&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2002, Gliatech filed for bankruptcy to manage its financial restructuring options, including the orderly auction and sale of assets to meet its obligations to creditors. Gliatech had previously stated in April 2002 that it did not expect that sales of its products and pipeline projects would sustain the company; however, shortly before the Chapter 11 filing, the company confirmed that the status of its drug development programs was to remain unchanged [&lt;ulink linkID="449905" linkType="reference"&gt;449905&lt;/ulink&gt;], [&lt;ulink linkID="450307" linkType="reference"&gt;450307&lt;/ulink&gt;], [&lt;ulink linkID="450758" linkType="reference"&gt;450758&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16483">Gliatech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="238">Obesity</Indication><StatusDate>2002-11-07T00:00:00.000Z</StatusDate><Source id="469832" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2004-05-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16483">Gliatech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2000-11-06T14:45:54.000Z</StatusDate><Source id="388484" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2002-11-07T00:00:00.000Z</StatusDate><Source id="469832" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00917"><Name>Histamine H3 receptor</Name><SwissprotNumbers><Swissprot>P58406</Swissprot><Swissprot>Q9JI35</Swissprot><Swissprot>Q9QYN8</Swissprot><Swissprot>Q9Y5N1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Licensing information updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="16483">Gliatech Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C1CCC(CC1)COC(=O)N[C@@H]2C[C@H]2C3CNC=N3</Smiles></StructureSmiles><Deals><Deal id="103633" title="Merck to develop Gliatech's histamine H3 and H5 small molecules and glycine transporter programs "/></Deals><PatentFamilies><PatentFamily id="1879041" number="WO-00215905" title="The use of histamine H3 inverse receptor agonists for the control of appetite and treatment of obesity"/><PatentFamily id="550362" number="WO-2006058023" title="Treatment of stroke with histamine H3 inverse agonists or histamine H3 antagonists"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gliatech Inc" id="16483"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>